• 10x Genomics Acquires Spatial Genomics Company

    Bio-IT World Brief   10x Genomics has acquired Stockholm-based Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. The new field enables researchers to not only see what is in a cell but how cells are organized in relation to one another, offering up invaluable insight into understanding disease.

    Dec 10, 2018

  • A Mature Capital Structure Positions Bio-IT Startups For Success

    Bio-IT World Contributed Commentary | By establishing a mature capital structure reflecting a healthy balance of both equity and debt, early-stage bio-IT companies can project long-term strength and vision that helps to favorably position them with their stakeholders.

    Dec 6, 2018

  • GSK Bags Tesaro For $5B As It Leaps Back Into Commercial Oncology, Beefs Up Cancer Drug Pipeline

    Endpoints News | GlaxoSmithKline has struck a deal to buy Tesaro in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market as it stakes out a big new role for itself in the booming cancer field.

    Dec 5, 2018

  • OmniTier Debuts CompStor Novos Platform For De Novo Assembly-Based Variant Calling

    Bio-IT World News Brief | OmniTier has debuted the CompStor Novos platform for de novo assembly-based variant calling in whole genome sequencing applications.

    Dec 5, 2018

  • Despite CRISPR Baby Controversy, Harvard University Will Begin Gene-Editing Sperm

    MIT Technology Review | Even as a furious debate broke out in China over gene-edited babies, some scientists in the US are also hoping to improve tomorrow's children.

    Nov 30, 2018

  • Facing Backlash, Chinese Scientist Defends Gene-Editing Research On Babies

    NPR.org | He Jiankui, who shocked the world by asserting he had genetically edited twin girls, faced growing criticism from other researchers as he spoke at a scientific conference in Hong Kong.

    Nov 28, 2018

  • UberCloud, The Wellcome Sanger Institute, Panasas, And More: News From November 2018

    Bio-IT World | November featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including UberCloud, the Wellcome Sanger Institute, Panasas, and more.

    Nov 28, 2018

  • Claim Of CRISPR'ed Baby Girls Stuns Genome Editing Summit

    STAT | A researcher's claim that he used genome editing to alter DNA of human embryos, resulting in the birth a few weeks ago of twin girls, stunned scientists.

    Nov 26, 2018

  • Single-Cell Sequencing Is Opening Up New Avenues For Potential Treatments

    STAT | By quickly analyzing thousands - even millions - of cells, it's now possible to visualize the specific cellular culprits for any given disease.

    Nov 21, 2018

  • Researchers Assemble Pan-Genome From 910 Humans Of African Descent Using Deep Sequencing

    Bio-IT World | Researchers from Johns Hopkins University and other institutions recently conducted a study that used a deeply sequenced dataset of over 900 individuals of African descent to construct a set of DNA sequences that is missing from the current reference human genome.

    Nov 20, 2018

  • Data Science Foundation: Findable, Accessible Data

    Bio-IT World | Adam Margolin, the new Director of the Icahn Institute for Data Science & Genomic Technology, says the most foundational aspect of data science is not number crunching, but actually finding to data. If we could integrate data coming out of all of our molecular profiling studies, for instance, Margolin says, it would revolutionize our ability to understand patients. 

    Nov 19, 2018

  • Did IBM overhype Watson Healths AI promise?

    Computerworld | IBM's Watson Health division has been under fire for not delivering on its promise to use AI to enable smarter, more personalized medicine. But IBM officials maintain that hospitals are seeing benefits.

    Nov 14, 2018

  • Celgene Doubles Down on Dragonfly Pays $50M to Expand Cancer Pact

    Xconomy | Celgene's collaboration with Dragonfly Therapeutics is less than 18 months old, but the pharmaceutical company is already expanding the alliance. Celgene

    Nov 14, 2018

  • Machine Learning Predicts How DNA Breaks Under CRISPR

    Bio-IT World | In a study published yesterday in Nature, researchers created a machine-learning model—inDelphi—that predicts how human and mouse cells will respond to CRISPR-induced breaks in DNA.

    Nov 8, 2018

  • NVMe: Powering Genomics And Life Sciences

    Bio-IT World Contributed Commentary | Most organizations require high speed computing capabilities. NVMe delivers this capability to businesses by tapping into the power and speed of flash technology and increasing data processing speeds by up to 100 times when compared to spinning disk media.

    Nov 7, 2018

  • A Billionaires Dying Wish A $10 Million Prize To Fight Brain Diseases

    Forbes | Named for late billionaire Richard Rainwater, the Rainwater Prize Program has launched to help find a cure for a rare brain disease.

    Nov 6, 2018

  • In conversation with… Harold Varmus

    Mosaic | Alok Jha talks to Harold Varmus, Nobel Prize-winning cancer researcher and current Director of the US National Cancer Institute.

    Nov 6, 2018

  • Illumina Acquires PacBio, Discusses Future In Investor Call

    Bio-IT World | Yesterday Illumina announced its intention to acquire Pacific Biosciences. Both companies presented the details and took questions during an investor call.

    Nov 2, 2018

  • New Head For Renamed Icahn Institute At Mount Sinai

    Bio-IT World | Mount Sinai has named a new head for its Icahn Institute, and renamed the effort the Icahn Institute for Data Science and Genomic Technology. Adam Margolin will lead the new enterprise-wide program, whose 10-year plan includes 55 new faculty and staff, new computational infrastructure, and an educational program to train master’s students and PhDs in biomedical data science.

    Nov 2, 2018

  • Illumina Buys PacBio For $1.2 Billion

    Bio-IT World News Brief | Illumina and Pacific Biosciences today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.

    Nov 1, 2018